TechCrunch : Alphabet’s record-breaking $85B raise for Google’s AI business is a

Alphabet’s record-breaking $85B raise for Google’s AI business is a helluva good signal

If Alphabet’s record-breaking $85 billion stock sale signals investor appetite for AI-related offerings — and it does — we can safely say that investors are voracious.

Google’s parent company had initially intended to sell a first tranche of $40 billion worth of various equity instruments — two different classes of shares, plus smaller “depositary shares” priced to be accessible to a broader range of investors. But the offering was so oversubscribed that it raised $45 billion instead, CEO Sundar Pichai said in a post on X on Monday. Among the buyers: Berkshire Hathaway, still known for its love of value investing, picked up $10 billion worth.

Alphabet plans to sell another $40 billion worth next quarter, for $85 billion total.

Even $80 billion would have topped the record for equity offerings previously set by Brazilian oil producer Petroleo Brasileiro SA, which raised $70 billion in 2010, Bloomberg reports.

Now, it’s true that these investors are buying shares of Alphabet, not shares in a younger, possibly debt-riddled AI startup. Alphabet is a very healthy business: $110 billion in revenue (with high profit margins) in Q1 alone, up 22% year-over-year.

Still, the money from this stock sale is earmarked for AI. “Part of our multi-year investment strategy to meet the AI opportunity ahead and support the demand we’re seeing from enterprises and consumers,” as Pichai described it. At Google I/O last month, he said the company expects to spend between $180 billion and $190 billion on capital expenditures — largely on AI infrastructure and data centers — before the year is out.

The timing matters beyond Alphabet itself. As Anthropic gets ready to go public, this enormously successful stock sale is a very good sign for the broader AI IPO pipeline. It indicates that public investors, particularly the deep-pocketed institutional ones, are ready to pony up.

The upcoming SpaceX IPO is expected to smash records for cash raised and valuation, and Anthropic’s deal is expected to do the same, possibly surpassing SpaceX. OpenAI is also waiting in the wings.

But all of this rests on public investors’ appetite — not just private VCs — remaining strong, and then staying that way. An unprecedented nearly $8 trillion in AI spending has been committed over the next five years. That money has to come from somewhere — and that somewhere includes individual company revenues, loans, and capital raised through stock sales. Whether public markets have the stomach to absorb that much, for that long, is the question that every AI company eyeing an IPO should be thinking about right now.

The Information : Nvidia Buys Enterprise Model-Maker Kumo AI for at Least $400 M

Nvidia Buys Enterprise Model-Maker Kumo AI for at Least $400 Million

The Takeaway
  • Nvidia acquires enterprise predictive AI startup Kumo AI for over $400 million.
  • Kumo AI specializes in predictive AI for enterprise structured data.
  • Acquisition expands Nvidia’s AI models optimized for its hardware.

Nvidia has bought Kumo AI, a five-year-old startup that sells predictive AI software to enterprises, for more than $400 million, said a person with knowledge of the deal.

The acquisition, first revealed by an Nvidia executive in a LinkedIn post on Tuesday, should expand Nvidia’s roster of AI models that can be optimized for Nvidia hardware and offered to enterprises for further customization.

Nvidia has invested heavily in its open-weight models, such as its Nemotron models, but Kumo’s models are proprietary. They’re tailored to answer questions on structured business data, such as customer information and payment data, which are generally harder for large language models to parse.

Kumo’s CEO and Nvidia declined to comment.

It’s unclear exactly how Nvidia will use Kumo’s models. It could use them in its AI Foundry software, which aims to help companies build custom AI models by combining their own data and domain-specific knowledge, such as genomic data, with Nvidia software, existing open-source models and synthetic, or AI-generated, data. Nvidia could also use Kumo’s researchers to help develop new, business-focused Nvidia foundation models.

Corporate data generally consists of structured layers of tables connected to other tables, and a company generally needs troves of proprietary data to train models on answering questions, such as on the likelihood that a customer will cancel. Kumo attempted to solve this problem by supplementing its training data with synthetic data from simulated enterprise environments and pairing that with graph machine learning techniques the founders developed at Stanford, the company has said.

Kumo released its latest model, KumoRFM-2, in April and says it counts DoorDash, Reddit, Databricks and Snowflake among its customers and partners. It raised $37 million from Sequoia Capital, Ron Conway’s SV Angel and others, including at a $250 million valuation in 2022, according to PitchBook.

Kumo founders Vanja Josifovski, former CTO of Pinterest; Jure Leskovec, a Stanford University professor, and Hema Raghavan, previously an AI lead at LinkedIn, have been working at Nvidia since May, according to their LinkedIn.

The Kumo deal is in line with Nvidia’s track record of smaller acquisitions. The company spent a total of around $3 billion on acquisitions over the last five years, according to its securities filings. Also, late last year it agreed to pay $20 billion to license technology from inference chip designer Groq,

The Information : Meta Looks to Charge Up to $200 a Month for Planned ‘Hatch’ AI

Meta Looks to Charge Up to $200 a Month for Planned ‘Hatch’ AI Agent

The Takeaway
  • Meta’s planned Hatch AI agent could cost up to $200 monthly, rivaling top AI subscriptions.
  • Hatch will create software tools and handle tasks such as managing schedules and sending emails for users.
  • A premium version of Hatch would be part of Meta’s efforts to diversify revenue beyond advertising.

Meta Platforms is considering charging up to $200 a month for its planned consumer version of the OpenClaw AI agent tool, according to internal documents, an ambitious target that would rival top tier offerings from established AI giants.

The product, currently called Hatch, could launch with tiered pricing including the $199.99 premium subscription that would include higher usage limits, according to the documents reviewed by The Information and a person familiar with the matter, who noted that final pricing decisions haven’t been made.

Hatch would handle a range of tasks from vibe coding new software tools to scheduling events on users’ calendars or sending emails on their behalf, according to images of test versions also viewed by The Information. Users can describe what they want in plain language, similar to the way vibe coding apps work, such as “build me a fitness tracker,” and Hatch generates a working tool.

Charging for a premium version of Hatch would place Meta in more direct competition with OpenAI, Anthropic and other AI firms that already have built large customer bases for their AI coding and agent products. Both OpenAI’s ChatGPT Pro subscription and the highest-end version of Anthropic’s Claude Max plan cost $200 per month.

As previously reported, Meta is conceiving of Hatch as essentially a consumer version of OpenClaw, the open-source agent tool that has become popular in tech circles but complicated to use. The planned product is part of Meta Chief Executive Mark Zuckerberg’s broader effort to develop new revenue streams to help pay for its enormous investments in AI infrastructure and model development.

The documents, which date from April and May, show that Hatch also includes a customizable feed or dashboard to display the tools created by the agent, similar to OpenClaw, which lets users pick from capabilities called “skills” where modular add-ons let AI agents access tools, automate workflows, and interact with third-party services. These skills will allow Hatch to carry out specific tasks, such as creating a travel itinerary, according to the person familiar with the matter.

Meta-Powered AI

In its development so far, Hatch has been powered by Anthropic’s Claude Opus 4.6 and Claude Sonnet 4.6 models. When launched, Hatch will be powered by Meta’s latest AI model, Muse Spark, the person said.

Upgrade to ask Deep Research to…
What risks surround SpaceX’s massive Anthropic deal?
What threatens startups using Anthropic and OpenAI?
What could derail the 2026 AI IPOs?
How are AI costs hurting SaaS vendors?
In an April internal memo, product marketing manager Jennifer Lin said Meta was working to expand the agentic capabilities of skills, but that no final decisions had been made on branding, and that the name “Meta AI Skills” had not been confirmed.

The internal documents indicate Meta was initially targeting a U.S. launch in April. A separate internal memo from early May said Meta was aiming for a controlled rollout to about 10 businesses to pilot the product, followed by a broader launch with finalized branding and product naming in July, although the launch date could change.

In one of the internal documents, Meta describes plans to launch a paid premium subscription tier, “Hatch Plus,” which would offer significantly higher usage limits than the free version—between five and ten times more daily capacity. The document also states that token allowances would reset each billing cycle and would not roll over, “similar to Claude, OpenAI, etc.”

Zuckerberg has said that Meta intends to build AI agents for business as well as individual users, whom he sees as central to his vision for what he calls personal superintelligence. “Our goal is not just to deliver Meta AI as an assistant, but to deliver agents that can understand your goals and then work day and night to help you achieve them,” he said in Meta’s second-quarter earnings call in April.

The Meta chief also dropped hints about users being able to vibe-code their own tools, saying that whether people use its personal or business agents to achieve their goals, he believes there will be a “massive increase in entrepreneurship from people creating new things that they’ve always wanted to exist but previously didn’t have the tools to bring into the world.”

Meta has increasingly focused on turning its AI investments into revenue-generating products as the company continues to invest heavily in infrastructure, chips, and model development. Its AI capabilities helped drive strong growth in 2025, when revenue topped $200 billion. But almost all of that still comes from advertising, and Meta is under investor pressure to add new revenue streams to justify its capital expenditures, which it has said could reach $145 billion this year, about double the level in 2025.

The company has already begun rolling out paid features for its AI offerings, including subscription plans tied to its Meta AI chatbot, which is accessible through Facebook, Instagram and WhatsApp. This week, Meta also said it is expanding existing AI agent tools that businesses can use within its platforms, extending its Meta Business Agent product to Instagram and launching Meta Business Agent Platform.

The agents in those tools can recommend products, close sales, book appointments, answer customer questions, and send personalized marketing messages, as well as provide business owners with overnight chat summaries and performance insights. The Meta Business Agent tools are currently free, and Meta said it plans to introduce paid subscriptions in the coming months. Those tools are intended for use on Meta’s own platforms, whereas Hatch will also be able to function in the wider digital world.

>>> Goldman Raises Kospi Target to 12000, Upgrades Taiwan to Overweight

Goldman Raises Kospi Target to 12000, Upgrades Taiwan to Overweight

Goldman Sachs raises its 12-month target for South Korea’s Kospi stock benchmark to 12000 from 9000 and upgrades Taiwan’s benchmark Taiex to overweight with a 51000 target. “We lean into north Asia where earnings growth is strongest,” GS analysts led by Timothy Moe say in a note, citing AI-driven surging profits in the tech-heavy markets. This year, the Kospi has more than doubled while the Taiex is up around 60%, they note. GS expects Korea to lead Asia with profit growth of 320% in 2026, followed by Taiwan at 48%. The bank cautions that recent market gains raise the risk of a correction, recommending derivative overlays to hedge against a possible sharp pullback.

>>> Abivax : Guggenheim Call - from X

https://x.com/seedy19tron/status/2062233372399632421?s=48&t=TyS9gd0pKsNaRNM_CyjCiA

team on the gugg fireside:

- part B will be released in the coming days, has an additional 400 + 200 (relapse) pt data which will further alleviate investor concerns re safety (all on drug no pbo)
- 2 yr rat carc data and 6 mo mouse data no signals , further evidence that there is no correlation , the only lesions (mostly rash) came up (none cancerous) at what would be the human equivalent of much much higher than 50mg exposure
- very confident no black box and don’t think warning either , cited other cases where the malignancies were similar or higher without a black box or even a warning
- part B presentation will also have an updated safety table from part A , where the malignancies will be updated to reflect the correct information
- meeting pre NDA scheduled
- looping in some seasoned FDA folk in gastro for guidance and help to get it right

There were other tidbits that can happily allow me to say that the market initial reaction got it completely wrong (mgmt also to an extent but it caught them completely off guard) but this provides a second generational opportunity with
$abvx

PoS for Crohns higher , no bb or even a warning (most likely scenario just fyi) this could do $10b in peak sales.

Also I actually think the setup to buy here is better than buying at $8 (knowing the blinded blended data) because we KNOW all things considered is the best oral in UC and the magnitude of effect means that it’s very likely it will be more than fine in CD as well.

To conclude my review of all evidence drives to only one conclusion Obe does not cause cancer or accelerate it. Today’s price action reflective of the narrative correcting and this only the beginning of the stock recovering to levels reflective of the unbelievable asset they own.